Vernalis Research is a world leader in structure- and fragment-based drug discovery. We have generated six development candidates in the past six years and cell active lead compounds against 15 different targets. Our successes include projects in close collaboration with companies such as Lundbeck, Novartis, Servier, Genentech, Asahi Kasei Pharma and Taisho. Our strengths are in developing and applying the most appropriate structure-based methods to work with our partners to solve problems in drug discovery.
For more information please visit www.vernalis-research.com